°í°´´Ô¿¡°Ô ´Ù¾çÇÑ ¼Ò½Ä°ú »ý»ýÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
| Á¦¸ñ | Natural Product Research (Neuroprotective Effects of GMAS-01 against Oxidative Stress) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ÀÛ¼ºÀÚ | igenome09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ÀÛ¼ºÀÏÀÚ | 2026-08-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
EXECUTIVE SUMMARY: GMAS-01 NEUROPROTECTION A Scientific Synthesis on the
Protective Effects of Eleutherococcus sessiliflorus, Phragmites australis, and
Pinus densiflora against Oxidative Stress in Neuronal Cells 1. Introduction and
Objectives
Neurodegenerative
diseases are intimately linked to oxidative stress-induced neuronal damage,
driven by an excess of reactive oxygen species (ROS) such as hydrogen peroxide
(H2O2) that overpower cellular antioxidant defense systems. This study
scientifically evaluates the neuroprotective mechanisms of GMAS-01, a novel
polyherbal formulation combining extracts from three traditional botanicals: Eleutherococcus sessiliflorus (ES,
Acanthopanax bark), Pinus densiflora
(PD, Korean Red Pine bark), and Phragmites
australis (PA, Reed rhizome) at an optimized weight ratio of 4:2:1. The
objective was to validate its therapeutic synergy, identify key bioactives via
HPLC, model ligand-protein interactions in silico, and elucidate protective
pathways in human SH-SY5Y neuroblastoma cells. 2. Phytochemical and In
Silico Characterization
HPLC-DAD analysis
identified three major bioactive marker compounds within the individual
extracts and the integrated GMAS-01 formulation. To substantiate these
findings, molecular docking was executed to evaluate binding affinities against
key neuropathological, apoptotic, and inflammatory protein targets compared to
Resveratrol (a classic antioxidant control). Notably, Caspase-9 (Casp-9), an
essential initiator caspase in mitochondrial apoptosis, was included as a
primary target to provide a holistic understanding of the anti-apoptotic
pathway. Table 1.
Phytochemical Quantities & Molecular Docking Affinity (kcal/mol)
3. In Vitro Neuroprotective
Mechanisms
Using human SH-SY5Y neuroblastoma cells as an established in vitro
model, acute oxidative stress was induced via exposure to 200 ¥ìM H2O2 (reducing
baseline cell viability to approximately 50%). GMAS-01 pre-treatment (12.5–200
¥ìg/mL) successfully mitigated cellular damage through several coordinated
pathways: ¡¤
Cell Viability Preservation: Pre-treatment with GMAS-01 significantly
enhanced cell viability in a concentration-dependent manner (p < 0.001 at
200 ¥ìg/mL), showing a more pronounced protective effect than the individual
herb extracts and effectively preserving neuronal membrane integrity. ¡¤
Apoptosis Suppression: Hoechst 33342 staining confirmed that GMAS-01
markedly decreased H2O2-induced apoptotic hallmarks, including chromatin
condensation, nuclear shrinkage, and nuclear fragmentation. ¡¤
Mitochondrial Potential Restoration: Mitochondrial Membrane Potential (MMP) was
assessed using Rhodamine 123. GMAS-01 significantly improved the H2O2-induced
loss of mitochondrial membrane potential (MMP), demonstrating its protective
effect on mitochondrial function. ¡¤
ROS Reduction and Antioxidant Enzyme Activity
Recovery: H2O2 elevated intracellular
reactive oxygen species (ROS) to double the control levels. GMAS-01
significantly reduced intracellular ROS levels and restored the activities of
key antioxidant enzymes, including Superoxide Dismutase (SOD), Glutathione
Peroxidase (GPx), and Catalase (CAT), which had been reduced by oxidative
stress. ¡¤
Apoptotic Gene Expression Modulation: GMAS-01 pre-treatment down-regulated
pro-apoptotic genes (Bax, caspase-3, and caspase-9) while up-regulating the
anti-apoptotic gene Bcl-2 at the mRNA expression level. ¡¤
Pathological Pathways Suppression: The formulation significantly prevented the
H2O2-induced overexpression of NF-¥êB and amyloid precursor protein (APP) genes
(p < 0.05), which are key biomarkers in neurodegenerative pathways. 4. Conclusion and Future
Directions
This study
rigorously demonstrates that the GMAS-01 complex targets multiple
neuropathological sites simultaneously, producing a distinct synergistic
benefit over monoherbal therapies. While these results provide strong
scientific evidence for GMAS-01 as a promising therapeutic candidate for
neurodegenerative disorders, the current study's primary limitation is its
reliance on an SH-SY5Y cell model. Further studies using differentiated
neuronal models and in vivo experimental systems are needed to evaluate the in
vivo efficacy and clinical relevance of GMAS-01. 5. Scientific Attribution
& Research Source
This executive
summary represents a key scientific achievement co-authored by Genome and Natural Bio (Chairman Kyu Hyeong
Yoon) in collaboration with Kyung Hee University. The complete
peer-reviewed study is officially published in the SCI-indexed journal, Natural Product Research (2026).
Inquiries regarding detailed experimental methodology, full author lists, and
supplementary datasets can be verified via the publisher's digital object
identifier (DOI) link below. Original Publication DOI Link: https://doi.org/10.1080/14786419.2026.2674725 Çмú ¿ä¾à º¸°í¼: GMAS-01 ½Å°æº¸È£ È¿´É ¿À°¡ÇÇ, ³ë±Ù, Àû¼Û º¹ÇÕ ÃßÃâ¹°(GMAS-01)ÀÇ °ú»êȼö¼Ò À¯¹ß ½Å°æ¼¼Æ÷ »êÈ ½ºÆ®·¹½º º¸È£ ±âÀü¿¡ °üÇÑ °úÇÐÀû ±Ô¸í 1. ¼·Ð ¹× ¿¬±¸ ¸ñÀû
½Å°æÅðÇ༺ ÁúȯÀº °ú»êȼö¼Ò(H2O2) µî Ȱ¼º»ê¼ÒÁ¾(ROS)ÀÇ °úµµÇÑ ÃàÀûÀ¸·Î ¼¼Æ÷ ³» Ç×»êÈ ¹æ¾î ü°è°¡ ºØ±«ÇÏ¿© ¹ß»ýÇÏ´Â ½Å°æ¼¼Æ÷ ¼Õ»ó°ú ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÇ¾î ÀÖ½À´Ï´Ù. º» ¿¬±¸´Â ÀüÅë õ¿¬¹°ÀÎ ¿À°¡ÇÇ(ES,
Eleutherococcus sessiliflorus), Àû¼Û(PD,
Pinus densiflora), ³ë±Ù(PA, Phragmites australis )À» Çö´ë ¾à¸®ÇÐÀû À̷п¡ ÀǰÅÇÏ¿© 4:2:1ÀÇ ÃÖÀû Áß·® ºñÀ²·Î ¹èÇÕÇÑ »õ·Î¿î »ý¾à º¹ÇÕÁ¦Á¦ GMAS-01ÀÇ ½Å°æº¸È£ È¿°ú¿Í ±× ¸ÞÄ¿´ÏÁòÀ» °úÇÐÀûÀ¸·Î °ËÁõÇÏ¿´½À´Ï´Ù. HPLC ºÐ¼®À» ÅëÇØ º¹ÇÕ¹°ÀÇ ÁöÇ¥ ¼ººÐÀ» Á¤·®ÈÇϰí, ºÐÀÚ µµÅ·(In Silico)À» ÅëÇØ Ç¥Àû ´Ü¹éÁú°úÀÇ °áÇÕ ¼º´ÉÀ» ±Ô¸íÇÑ ÈÄ, Àΰ£ ½Å°æ¸ð¼¼Æ÷Á¾ SH-SY5Y ¼¼Æ÷¸¦ Ȱ¿ëÇØ ¼¼Æ÷ ¼öÁØ¿¡¼ÀÇ ´Ù°¢Àû º¸È£ ±âÀüÀ» ÀÔÁõÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÏ¿´½À´Ï´Ù. 2. ÁöÇ¥¼ººÐ ºÐ¼® ¹× ºÐÀÚ µµÅ·(Molecular Docking) °á°ú
HPLC-DAD Á¤·® ºÐ¼® °á°ú, º¹ÇÕ ÃßÃâ¹° GMAS-01 ³»¿¡¼ ÇÙ½É ÁöÇ¥ ¼ººÐÀÎ ¾ÆÄÅä»çÀ̵å D, p-Äí¸¶¸£»ê, Ä«Å×ŲÀÌ ¸íÈ®È÷ µ¿Á¤µÇ¾ú½À´Ï´Ù. À̵éÀÇ ÀÛ¿ë ±âÀüÀ» ¿øÀÚ ¼öÁØ¿¡¼ ¿¹ÃøÇϱâ À§ÇØ ÄÄÇ»ÅÍ ½Ã¹Ä·¹ÀÌ¼Ç ±â¹Ý ºÐÀÚ µµÅ·À» ¼öÇàÇÏ¿´À¸¸ç, »êÈ ½ºÆ®·¹½º, ¿°Áõ ¹× ¼¼Æ÷»ç¸ê °ü·Ã ÇÙ½É ´Ü¹éÁú Ç¥Àû¿¡ ´ëÇÑ °áÇÕ ¿¡³ÊÁö¸¦ »êÃâÇÏ¿© ´ëÁ¶ ¾à¹°ÀÎ ·¹½ºº£¶óÆ®·Ñ(Resveratrol)°ú ºñ±³ ºÐ¼®ÇÏ¿´½À´Ï´Ù. ƯÈ÷ ¹ÌÅäÄܵ帮¾Æ °æ·Î¸¦ ÅëÇÑ ¼¼Æ÷»ç¸ê À¯µµ ¹× ¾ïÁ¦¿¡ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÏ´Â Caspase-9 ´Ü¹éÁú°úÀÇ °áÇÕ È°¼ºÀ» ºÐ¼® ´ë»ó¿¡ Ãß°¡ÇÏ¿© ÇÑ Â÷¿ø ³ôÀº ¸ÞÄ¿´ÏÁò ÇØ¼®À» ¿Ï¼ºÇÏ¿´½À´Ï´Ù. Table 2. GMAS-01 ±¸¼º ¼ººÐÀÇ Á¤·® ¹× ÁÖ¿ä ´Ü¹éÁú Ç¥Àû °áÇÕ Ä£È·Â (kcal/mol)
3. ½ÃÇè°ü ³»(In Vitro) ½Å°æº¸È£ ¸ÞÄ¿´ÏÁò
Àΰ£ ½Å°æ¸ð¼¼Æ÷Á¾ SH-SY5Y ¼¼Æ÷ÁÖ¸¦ ¸ðµ¨·Î »ï¾Æ 200 ¥ìM °ú»êȼö¼Ò(H2O2)¸¦ ó¸®ÇÏ¿© À¯µµµÈ »êÈ ½ºÆ®·¹½º »óȲ¿¡¼ GMAS-01 º¹ÇÕÁ¦Á¦ÀÇ »çÀü ó¸®(12.5–200 ¥ìg/mL)¸¦ ÅëÇØ µµÃâµÈ ÇÙ½É ¸ÞÄ¿´ÏÁòÀº ´ÙÀ½°ú °°½À´Ï´Ù. ¡¤
¼¼Æ÷ »ýÁ¸À²(Viability)
º¸Á¸: H2O2¿¡ ´Üµ¶ ³ëÃ⠽à ¼¼Æ÷ »ýÁ¸À²ÀÌ 50% ¼öÁØÀ¸·Î ±Þ°¨ÇÑ ¹Ý¸é, GMAS-01À» 200 ¥ìg/mL ³óµµ·Î Àüó¸®ÇÑ ¼¼Æ÷´Â »ýÁ¸·ÂÀÌ À¯ÀǹÌÇÏ°Ô Çâ»óµÇ¾úÀ¸¸ç(p < 0.001), °³º° »ý¾à ÃßÃâ¹°°ú ºñ±³ÇÏ¿© GMAS-01¿¡¼ º¸´Ù ¶Ñ·ÇÇÑ ¼¼Æ÷ º¸È£ È¿°ú°¡ °üÂûµÇ¾ú½À´Ï´Ù. ¡¤
¼¼Æ÷ÀÚ¸ê»ç(Apoptosis)ÀÇ ÇüÅÂÇÐÀû ¾ïÁ¦: Hoechst 33342 ¿°»ö¹ý °á°ú, H2O2·Î À¯¹ßµÈ ÀüÇüÀûÀÎ ¼¼Æ÷»ç¸ê Ư¡ÀÎ ¿°»öÁú ÀÀÃà, ÇÙ ¼öÃà ¹× ÇÙ ÆÄÆíÈ Çö»óÀÌ GMAS-01 Àü󸮱º¿¡¼ ÇöÀúÈ÷ ¾ïÁ¦µÊÀ» ½Ã°¢ÀûÀ¸·Î È®ÀÎÇÏ¿´½À´Ï´Ù. ¡¤
¹ÌÅäÄܵ帮¾Æ ¸· ÀüÀ§(MMP) ȸº¹ ¹× ºØ±« ¹æÁö: Rhodamine 123 ¿°»ö ºÐ¼®À» ÅëÇØ »êÈ ½ºÆ®·¹½º·Î ÀÎÇØ °¨¼ÒÇÑ ¹ÌÅäÄܵ帮¾Æ ¸· ÀüÀ§(MMP)¸¦ GMAS-01ÀÌ À¯ÀÇÇÏ°Ô °³¼±ÇÏ´Â È¿°ú°¡ °üÂûµÇ¾ú½À´Ï´Ù. ¡¤
Ȱ¼º»ê¼Ò(ROS) °¨¼Ò ¹× Ç×»êÈ È¿¼Ò Ȱ¼º ȸº¹: ¼¼Æ÷ ³» ROS ¼öÁØÀ» À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÄ×À¸¸ç, »êÈ ½ºÆ®·¹½º·Î °¨¼ÒÇÑ ½´ÆÛ¿Á»çÀÌµå µð½º¹ÂŸÁ¦(SOD), ±Û·çŸƼ¿Â °ú»êÈÈ¿¼Ò(GPx), īŻ¶ó¾ÆÁ¦(CAT)ÀÇ È°¼ºÀ» À¯ÀÇÇÏ°Ô È¸º¹½ÃÄ×½À´Ï´Ù. ¡¤
¼¼Æ÷ÀÚ¸ê À¯ÀüÀÚ Á¶Àý ¹× ½Å°æ¿°Áõ °æ·Î(NF-¥êB, APP) ¾ïÁ¦: RT-qPCR Á¤·® ºÐ¼®À» ÅëÇØ ¼¼Æ÷»ç¸êÀ» ÃËÁøÇÏ´Â Bax,
caspase-3, caspase-9 À¯ÀüÀÚ ¹ßÇöÀ» °·ÂÇÏ°Ô ¾ïÁ¦Çϰí, ¼¼Æ÷»ç¸êÀ» ¸·´Â Bcl-2 À¯ÀüÀÚ ¹ßÇöÀ» Áõ°¡½ÃÄ×½À´Ï´Ù. ³ª¾Æ°¡, ½Å°æ¿°ÁõÀ» ¸Å°³ÇÏ´Â ÇÙ½É °æ·ÎÀÎ NF-¥êB À¯ÀüÀÚ °ú¹ßÇö°ú ¾ËÃ÷ÇÏÀÌ¸Ó À¯¹ß¿¡ °ü¿©ÇÏ´Â APP(¾Æ¹Ð·ÎÀ̵å Àü±¸ ´Ü¹éÁú) À¯ÀüÀÚ ¹ßÇöÀ» Àü»ç ¼öÁØ¿¡¼ À¯ÀÇÇÏ°Ô ÇÏÇâ Á¶ÀýÇÏ¿´½À´Ï´Ù. 4. ÇмúÀû °¡Ä¡ ¹× ¿¬±¸ÀÇ ÇѰèÁ¡
º» ¿¬±¸´Â ¿À°¡ÇÇ, Àû¼Û, ³ë±ÙÀÇ ´ÙÁß Ç¥Àû ¹× ½Ã³ÊÁö È¿°ú¸¦ Çö´ë ÇÑ¹æ ¾à¸®ÇÐ °üÁ¡°ú ºÐÀÚ »ý¹°ÇÐÀû ±â¹ýÀ» °áÇÕÇÏ¿© ¸íÈ®È÷ ±Ô¸íÇß½À´Ï´Ù. ´Ù¸¸, º» ¿¬±¸´Â SH-SY5Y ¼¼Æ÷ÁÖ¸¦ Ȱ¿ëÇÑ ½ÃÇè°ü ³»(In vitro) ½ÇÇè¿¡ ±â¹ÝÇÑ °á°úÀ̹ǷÎ, ½ÇÁ¦ »ýü ³»(In vivo) È¿´É°ú ÀÓ»óÀû À¯È¿¼ºÀ» È®ÀÎÇϱâ À§Çؼ´Â ÇâÈÄ ºÐÈµÈ ½Å°æ¼¼Æ÷ ¹× »ýü ³» ¸ðµ¨À» ÀÌ¿ëÇÑ Ãß°¡ ¿¬±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. 5. Çмú ¿¬±¸ Á¤º¸ ¹× Ãâó
º» ¿ä¾à º¸°í¼´Â °Ô³ð¾Ø³»Ãß·²¹ÙÀÌ¿À(ȸÀå À±±ÔÇü) ¿¬±¸ÁøÀÌ °øµ¿ Âü¿©ÇÏ¿© SCI±Þ ±¹Á¦ Àú¸í ÇмúÁöÀÎ Natural Product Research (2026³â °ÔÀç)¿¡ °ø½Ä ¹ßÇ¥ÇÑ °øµ¿ ¿¬±¸ ¼º°ú¸¦ ¹ÙÅÁÀ¸·Î ÀÛ¼ºµÇ¾ú½À´Ï´Ù. »ó¼¼ÇÑ Àüü ³í¹® ¿øÀúÀÚ Á¤º¸ ¹× ºÎ¼Ó µ¥ÀÌÅÍ´Â ¾Æ·¡ ¿Â¶óÀÎ µðÁöÅÐ ÁÖ¼Ò(DOI) ¸µÅ©¸¦ ÅëÇØ Á¤½Ä ÇмúÁö ¿ø¹®¿¡¼ È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. ¿ø¹® DOI ¸µÅ©: https://doi.org/10.1080/14786419.2026.2674725 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ÷ºÎÆÄÀÏ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||